title: Case Report: Reversible cabergoline-associated cardiac valvulopathy post drug discontinuation.
abstract: We present a case of a 21 year old male patient diagnosed with a 2.2 cm prolactin-secreting adenoma in contact with the optic chiasm. The patient was treated with up to 6mg/week of cabergoline (total cumulative dose 814 mg) and developed mild valvulopathy. Valvulopathy was subsequently reversed after discontinuation of cabergoline therapy.
authors.affiliation: Northwest Pituitary Center, Oregon Health & Science University, Portland, Oregon, 97239, USA ; Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, 97239, USA.
authors.forename: Chris G
authors.initials: CG
authors.lastname: Yedinak
authors.affiliation: Northwest Pituitary Center, Oregon Health & Science University, Portland, Oregon, 97239, USA ; Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, 97239, USA.
authors.forename: Shirley
authors.initials: S
authors.lastname: McCartney
authors.affiliation: Department of Medicine, Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University, Portland, Oregon, 97239, USA.
authors.forename: Troy H
authors.initials: TH
authors.lastname: Dillard
authors.affiliation: Department of Cardiovascular Medicine, Oregon Health & Science University, Portland, Oregon, 97239, USA.
authors.forename: Kevin S
authors.initials: KS
authors.lastname: Wei
authors.affiliation: Northwest Pituitary Center, Oregon Health & Science University, Portland, Oregon, 97239, USA ; Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, 97239, USA ; Department of Medicine, Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University, Portland, Oregon, 97239, USA.
authors.forename: Maria
authors.initials: M
authors.lastname: Fleseriu